Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Epidermal Growth Factor Receptor
76%
EZH2
57%
Phosphotransferase
52%
Kinase
52%
Carcinogenesis
43%
Poly ADP Ribose Polymerase
36%
Drive
36%
PD-L1
29%
Methylation
28%
Mammalian Target of Rapamycin
27%
Transcription Factor EZH2
27%
AMP-activated Protein Kinase
27%
Mesenchymal-Epithelial Transition
25%
Upregulation
25%
Messenger RNA
23%
Protein Kinase B
22%
Gene Expression
22%
Cell Migration
22%
PARP1
19%
Immunity
19%
Epigenetics
19%
Tumor Necrosis Factor
18%
Ribonuclease
18%
CXCR4
18%
Histone H3
18%
STAT3
18%
Long Non-Coding RNA
18%
Glycogen Synthase Kinase 3
18%
Downregulation
18%
Tumor Progression
17%
Overall Survival
17%
SSX2
17%
Transcription Factor
17%
Cell Proliferation
17%
SSX1
16%
Drug Resistance
15%
Methyltransferase
15%
T Cell
15%
Glycosylation
15%
Lysine
14%
Gene Mutation
13%
Tumor Suppressor Protein
12%
Cyclin-Dependent Kinase
12%
Programmed Cell Death 1
11%
Tyrosine Phosphorylation
11%
Cytotoxic T Cell
11%
Growth Factor Receptor Inhibitor
11%
Immune Evasion
11%
Deglycosylation
11%
Keyphrases
Enhancer of Zeste Homolog 2 (EZH2)
65%
Breast Cancer
65%
Phosphorylation
48%
Triple-negative Breast Cancer
46%
Epidermal Growth Factor Receptor
44%
Programmed Death-ligand 1 (PD-L1)
42%
Methylation
28%
H3K27me3
27%
Cyclin-dependent Kinase 2 (CDK2)
27%
TSC1
27%
PARP Inhibitor (PARPi)
27%
Paraffin-embedded Tissue
27%
Synovial Sarcoma
27%
Tumorigenesis
25%
Cancer Cells
21%
Ovarian Cancer
20%
Breast Tumor
20%
Metastasis
20%
Human Breast Cancer
19%
Human Cancer
19%
Prognostic Value
19%
Pancreatic Cancer
19%
Hypoxia-inducible factor-1α (HIF-1α)
18%
Ribonuclease
18%
C-X-C Chemokine Receptor Type 4 (CXCR4)
18%
Murine Double Minute 2 (MDM2)
18%
SYT-SSX
18%
MTOR Pathway
18%
Oncogenic Function
18%
Site-specific Phosphorylation
18%
Tumor
17%
Epithelial-mesenchymal Transition
16%
Breast Cancer Patients
15%
Fusion Transcript
13%
Kinase Cascade
13%
Brain Metastases
13%
Cyclin D1 (CCND1)
13%
Inhibitor Resistance
13%
Quantitative PCR
13%
Histone H3
13%
Human Epidermal Growth Factor Receptor 2 (HER2)
12%
In Cancer
11%
Epidermal Growth Factor Receptor Inhibitors
11%
Malignancy
11%
Tyrosine Phosphorylation
11%
Trimethylation
11%
Tumor Metastasis
11%
Characteristic Sequence
10%
Sequence Analysis
10%
Cell-derived
10%
Medicine and Dentistry
Breast Cancer
65%
Epidermal Growth Factor Receptor
45%
Neoplasm
43%
Triple Negative Breast Cancer
36%
Cancer Cell
32%
Metastatic Carcinoma
32%
PARP Inhibitor
27%
Gastrointestinal Stromal Tumor
27%
PARP1
20%
Gene Mutation
20%
Pancreas Cancer
20%
Messenger RNA
18%
Synovial Sarcoma
18%
Transcription Factor EZH2
16%
Cancer
15%
Carcinogenesis
15%
Ovarian Cancer
15%
Cyclin D1
13%
Poly ADP Ribose Polymerase
13%
Histone H3
12%
Mammalian Target of Rapamycin
12%
Cyclin-Dependent Kinase
12%
Stromal Cell Derived Factor 1
12%
Recurrent Disease
11%
Reverse Transcription Polymerase Chain Reaction
11%
Lysine
11%
Therapy Resistance
11%
Programmed Death-Ligand 1
10%
Protein Kinase B
10%
Bone Metastasis
10%
Prostate Cancer
10%
Overall Survival
10%
calcium activated,phospholipid dependent protein kinase
10%
Lung Cancer
10%
Breast Tumor
10%
Fusion Gene
10%
Diagnosis
10%
Drug Resistance
9%
MCF-7
9%
Exon
9%
Hormone Therapy
9%
Pancreatic Cancer
9%
Tumor Invasion
9%
Targeting Protein
9%
Drive
9%
STAT3 Protein
9%
Mantle Cell Lymphoma
9%
Ferroptosis
9%
Pancreas Tumor
9%
Epidermal Growth Factor Receptor Kinase Inhibitor
9%
